产品
编 号：F145441
分子式：C13H22Br2Cl2N2
分子量：437.04
分子式：C13H22Br2Cl2N2
分子量：437.04
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 138356-21-5
产品详情
生物活性：
BD-1047 (dihydrobromide) is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.
体内研究：
BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.?BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).?BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity.Animal Model:Male Albino Swiss mice (50 days old, 25–28 g)
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg
Administration:Intraperitoneal injection
Result:Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.
体外研究：
BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.?BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.
BD-1047 (dihydrobromide) is a selective functional antagonist of sigma-1 receptor, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.
体内研究：
BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.?BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).?BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity.Animal Model:Male Albino Swiss mice (50 days old, 25–28 g)
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg
Administration:Intraperitoneal injection
Result:Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.
体外研究：
BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.?BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备